Seven Eight Capital’s AstraZeneca AZN Stock Holding History

Seven Eight Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,376	Closed	-$838K	–	60
2024 Q3	$838K	Buy	+5,376	New	+$868K	0.08%	450
2024 Q1	–	Sell	-11,024	Closed	-$1.48M	–	611
2023 Q4	$1.48M	Buy	11,024 +3,227	+41%	+$420K	0.17%	180
2023 Q3	$1.06M	Buy	7,797 +3,384	+77%	+$462K	0.12%	235
2023 Q2	$632K	Sell	4,413 -20,927	-83%	-$3.08M	0.1%	265
2023 Q1	$3.52M	Buy	+25,340	New	+$3.41M	0.73%	25
2022 Q3	–	Sell	-9,236	Closed	-$1.22M	–	484
2022 Q2	$1.22M	Buy	+9,236	New	+$1.21M	0.49%	46
2021 Q3	–	Sell	-5,203	Closed	-$623K	–	563
2021 Q2	$623K	Sell	5,203 -10,322	-66%	-$1.13M	0.09%	378
2021 Q1	$1.55M	Hold	15,525	–	–	0.36%	101
2020 Q4	$1.55M	Buy	+15,525	New	+$1.64M	0.35%	102
2017 Q1	–	Sell	-750	Closed	-$41K	–	521
2016 Q4	$41K	Buy	+750	New	+$42.6K	0.01%	520
2014 Q3	–	Sell	-1,700	Closed	-$126K	–	520
2014 Q2	$126K	Buy	+1,700	New	+$123K	0.12%	261
2014 Q1	–	Sell	-400	Closed	-$24K	–	284
2013 Q4	$24K	Buy	+400	New	+$21.7K	0.03%	481

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Seven Eight Capital's AZN Position: Q4 2024 in Review

Seven Eight Capital sold out of AstraZeneca (AZN) in Q4 2024, closing a stake of 5,376 shares — an estimated $838K sold.

Seven Eight Capital first reported a position in AZN in Q4 2013 and held it in 12 quarters. The position peaked at $3.52M in Q1 2023. 1,219 funds tracked by Wall St. Rank hold AZN as of Q4 2024.

Seven Eight Capital reported no remaining AstraZeneca position as of Q4 2024 after selling out during the quarter.
Seven Eight Capital sold 5,376 AstraZeneca shares in Q4 2024, an estimated $838K.
Seven Eight Capital first reported a position in AstraZeneca in Q4 2013 and held it in 12 quarters.
Seven Eight Capital's AstraZeneca position peaked at $3.52M in Q1 2023.
1,219 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.